We reinitiate our coverage on Bioxytran, Inc. (BIXT) with a fair valuation of $2.71 per share. Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drugs designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. It is also developing BXT-25, a glycopolymer that acts as an anti-necrosis drug by carrying oxygen to tissues even when blood flow is blocked and can reverse hypoxia (oxygen deficiency).
The full research report is available here.